All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
During the Virtual 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the ALL Hub spoke to Sara Ghorashian, University College London, London, UK. We asked, What are the major challenges for CAR T-cell therapies in Europe during the COVID-19 pandemic?
What are the major challenges for CAR T-cell therapies in Europe during the COVID-19 pandemic?
The COVID-19 pandemic has had an impact on the logistics of the already complex delivery of chimeric antigen receptor (CAR) T-cell therapies, by delaying both clinical studies and CAR T-cell accreditation for many centers. Ghorashian provides an overview of the challenges faced and dimensions to consider for the future, including vaccination, complications, and disease context.
Subscribe to get the best content related to ALL delivered to your inbox